The seroprevalence of HCV among injecting drug users in the years 2004–2008 in Slovakia

Czech version

Authors: K. Gazdíková ¹; †f. Gazdík ²; I. Kajaba ²; D. Hučková ³; Ľ. Okruhlica ⁴; D. Farkašová ¹
Authors‘ workplace: Fakulta ošetrovateľstva a zdravotníckych odborných štúdií Slovenskej zdravotníckej univerzity Bratislava, Slovenská republika, rektorka Dr. h. c. prof. PhDr. Dana Farkašová, CSc. ¹; Oddelenie imunológie a imunotoxikológie Slovenskej zdravotníckej univerzity Bratislava, Slovenská republika, rektorka Dr. h. c. prof. PhDr. Dana Farkašová, CSc. ²; HPL spol. s r. o., Bratislava, Slovenská republika, riaditeľ MUDr. Juraj Hanzen ³; Inštitút drogových závislostí, Centrum pre liečbu drogových závislostí Bratislava, Slovenská republika, riaditeľ MUDr. Ľubomír Okruhlica, PhD. ⁴
Published in: Vnitř Lék 2012; 58(3): 179-182
Category: Original Contributions

Overview

Introduction:
Virus of hepatitis C (HCV) is the leading cause of chronic liver disease, including cirrhosis and cancer, and the most common indication for liver transplantation. In industrialised countries, injecting drug use is currently the most important risk factor for infection with hepatitis C, resulting in high prevalence of hepatitis C among injecting drug users (IDUs). The aim of the study was to assess the seroprevalence of HCV infection and distribution of genotypes among IDUs in the years 2004–2008.

Probands and methods:
A total number of 846 probands, both sexes (590 males and 256 females) with mean age from 24 to 29 years were investigated in the years 2004–2008. Standard virological tests were performed.

Results:
The seroprevalence of anti-HCV positivity during the years 2004–2008 were in range 34–78% and positivity of HCV RNA assessed by PCR method were in range 17–71%. The genotypes distribution was in favour of genotype 3.

Conclusions:
In Slovakia IDUs represent risk group with high prevalence of hepatitis C. These results are comparable to those published in other European countries.

Key words:
prevalence – hepatitis C virus (HCV) – risk group of injecting drug users – HCV genotypes – distribution

Sources

1. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36 (5 Suppl 1): S30–S34.

2. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009; 29 (Suppl 1): 1–8.

3. Koncova-Fejdiova K, Kazar J, Gazdik F et al. Comparison of the HCV genotypes between active drug users and patients in the therapeutic process in the Slovak Republic in the years 2004–2005. J Clin Virol 2006; 36: 108.

4. Drogová závislosť – liečba užívateľa drog v SR 2009. Bratislava: Národné centrum zdravotníckych informácii 2010.

5. Hobstová J. Drogová závislost a infekční nemoci. Med pro Praxi 2010; 7: 368–371.

6. Gazdik F, Pijak M, Kazar J et al. Hepatitis C virus prevalence among general population and risk groups in the Slovak Republic. Hepatology 2001; 34: 559.

7. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148–162.

8. Sarkar K, Mitra S, Bal B et al. Rapid spread of hepatitis C and needle exchange programs in Kokata, India. Lancet 2003; 361: 1301–1302.

9. Sapatava E, Nelson KE, Tsertvadze T et al. Risk behaviours and HIV, hepatitis B, hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend 2006; 82 (Suppl 1): S35–S38.

10. Vassiliev ZP, Hagan H, Lyubenova A et al. Needle exchange use, sexual behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infection among Bulgarian injection drug users. Int J STD AIDS 2006; 17: 621–626.

11. CEEHRN. Hepatitis C among drug users in the new EU member states and neighbourhood: Recommendations for action. Central and Eastern European Harm Reduction Network. CEEHRN 2006.

12. Jauffret-Roustide M, Emmanuelli J, Quaglia M et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data – the ANRS-Coquelicot Study. Subst Use Misuse 2006; 41: 1603–1621.

13. van de Laar TJ, Langendam TW, Bruisten SM et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol 2005; 77: 509–518.

14. Výročná správa 2008: Stav drogovej problematiky v Európe. Luxemburg: Úrad pre vydávanie úradných publikácii Európskych spoločenstiev.

15. Krekulová L, Rehák V, Strunecký O et al. Current situation and trends in the hepatitis C genotype distribution among injecting drug users in the Czech Republic. Epidemiol Mikrobiol Imunol 2009; 58: 84–89.

16. Husa P. Virová hepatitda C. Klin Farmakol Farm 2009; 23: 30–34.

17. Vitous A, Hobstová J. Infekční onemocnení problémových uživatelů drog hospitalizovaných na infekčním oddělení FN Motol v období 2002––2005. Klin Mikrobiol Inf Lék 2007; 13: 70–75.

18. Sutton AJ, Gay NJ, Esmunds WJ et al. Modeling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis 2006; 6: 93.

19. Micalessi MI, Gérard C, Ameye L et al. Distribution of hepatitis C genotypes among injection drug users in contact with treatment centers in Belgium, 2004–2005. J Med Virol 2008; 80: 640–645.

20. Gazdíková K, Gazdík F, Hučková D et al. Prevalencia vírusových hepatitíd C a B u klientov resocializačných zariadení Slovenska. Psychiatria pre Prax 2010; 11: 136–138.

21. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J 2001; 345: 41–52.

22. Gazdik F, Bednarova A, Kazar J et al. Hepatitis C virus genotypes distribution among risk groups in the Slovak Republic. Hepatology 2001; 34: 559.

23. Gazdik F, Okruhlica Ľ, Laktiš K et al. Vysoká terapeutická účinnosť pegylovaného interferónu alfa a ribavirínu u bývalých, drogovo závislých jedincov s chronickou hepatitídou C. Via Practica 2006; 10: 478–482.

24. Husa P, Šlesinger P, Štroblová H et al. Ovlivnení úspešnosti léčby chronické hepatitidy C hmotností a pohlavím pacienta a výši vstupní viremie. Vnitř Lék 2006; 52: 590–595.

25. Urbánek P, Subhanová I, Janoušková E et al. Účinnost terapie pegylovaným interferonem a ribavirinem u pacientů s chronickou HCV infekcí. Vnitř Lék 2009; 55: 474–479.